Duration of Dual Antiplatelet Therapy in East Asians: Finding the Balance Between Effectiveness and Safety

J Cardiovasc Pharmacol. 2022 Aug 1;80(2):200-202. doi: 10.1097/FJC.0000000000001307.

Authors

Alessandra Tanzilli¹, Arturo Giordano^{2

3}, Giuseppe Biondi-Zoccai^{4

5}, Marco Bernardi¹

Affiliations

¹ Department of Cardiovascular Sciences, Sapienza University, Rome, Italy.
² Unità Operativa di Interventistica Cardiovascolare, Pineta Grande Hospital, Castel Volturno, Italy.
³ Unità Operativa di Emodinamica, Santa Lucia Hospital, San Giuseppe Vesuviano, Italy.
⁴ Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; and.
⁵ Mediterranea Cardiocentro, Napoli, Italy.

PMID: 35767711
DOI: 10.1097/FJC.0000000000001307

No abstract available

Publication types

Comment

MeSH terms

Asian People / genetics
Drug Therapy, Combination
Dual Anti-Platelet Therapy
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors* / adverse effects
Treatment Outcome

Substances

Platelet Aggregation Inhibitors